Q-omics provides the consensus-scored LINC00851 profile across patient tissues and cancer cell-line models. LINC00851 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, LINC00851 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, LINC00851 RNA expression shows 6,756 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, HNSC, and STAD as cancer lineages where LINC00851 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00851 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00851 survival associations across molecular data types. LINC00851 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00851 RNA expression–survival associations across cancer types. High LINC00851 expression shows unfavorable associations in LIHC, PAAD, KIRC and TGCT, but favorable associations in LUSC and BLCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for LINC00851 RNA expression.
This table summarizes LINC00851 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00851. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00851 shows lower tumor expression in LUAD and higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher LINC00851 RNA expression in tumor versus normal tissue (log2 FC = +0.164, t-test p = .026).
This table shows molecular features associated with LINC00851 in patient tissues and cancer cell lines. In patient samples, LINC00851 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
